1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. MediPal Holdings Corporation
  6. Summary
    7459   JP3268950007

MEDIPAL HOLDINGS CORPORATION

(7459)
  Report
Delayed Japan Exchange  -  02:00 2022-08-12 am EDT
1956.00 JPY   +0.82%
07/29MediPal Holdings Corporation acquired an unknown minority stake in Toshichi Co.,Ltd.
CI
06/27MEDIPAL : Integrated Report 2020
PU
03/30MEDIPAL HOLDINGS CORPORATION : Ex-dividend day for final dividend
FA
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
08/05/2022 08/08/2022 08/09/2022 08/10/2022 08/12/2022 Date
1905(c) 1920(c) 1925(c) 1940(c) 1956(c) Last
624 700 549 300 377 300 533 500 718 900 Volume
+0.69% +0.79% +0.26% +0.78% +0.82% Change
More quotes
Estimated financial data (e)
Sales 2023 3 324 B 24 878 M 24 878 M
Net income 2023 33 308 M 249 M 249 M
Net Debt 2023 - - -
P/E ratio 2023 13,0x
Yield 2023 2,28%
Sales 2024 3 362 B 25 167 M 25 167 M
Net income 2024 33 774 M 253 M 253 M
Net Debt 2024 - - -
P/E ratio 2024 12,6x
Yield 2024 2,34%
Capitalization 411 B 3 074 M 3 074 M
Capi. / Sales 2023 0,12x
Capi. / Sales 2024 0,12x
Nbr of Employees 12 801
Free-Float 75,6%
More Financials
Company
MEDIPAL HOLDINGS CORPORATION engages in the wholesale of pharmaceutical products, cosmetics and daily miscellaneous goods. The Company operates in three segments. The Ethical Pharmaceutical Wholesale segment is involved in the wholesale of pharmaceutical products, medical equipment and test reagents, the distribution and planning of specialty drugs, the construction of medical material database and others. The... 
More about the company
Ratings of MediPal Holdings Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about MEDIPAL HOLDINGS CORPORATION
07/29MediPal Holdings Corporation acquired an unknown minority stake in Toshichi Co.,Ltd.
CI
06/27MEDIPAL : Integrated Report 2020
PU
03/30MEDIPAL HOLDINGS CORPORATION : Ex-dividend day for final dividend
FA
2021Shinyei Kaisha announced that it expects to receive ¥170.7615 million in funding from M..
CI
2021MEDIPAL HOLDINGS CORPORATION : Ex-dividend day for interim dividend
FA
2021Nichi-Iko Pharmaceutical Co., Ltd. announced that it has received ¥5.23102 billion in f..
CI
2021Nichi-Iko Pharmaceutical Co., Ltd. announced that it expects to receive ¥5.23102 billio..
CI
2021Orizuru Therapeutics Inc. announced that it has received funding from Kyoto University ..
CI
2021Heartseed Inc. announced that it has received ¥4 billion in funding from a group of inv..
CI
2021MEDIPAL HOLDINGS CORPORATION : Ex-dividend day for final dividend
FA
2021CARADA medica Inc. announced that it expects to receive ¥6.157 billion in funding from ..
CI
2020MEDIPAL HOLDINGS CORPORATION : Ex-dividend day for interim dividend
FA
2020CRYOPORT : MEDIPAL HOLDINGS Partners with CRYOPORT to Bring Temperature-Controlled Supply ..
AQ
2020MediPal Holdings Corporation Partners with Cryoport, Inc. to Bring Temperature-Controll..
CI
2020MEDIPAL HOLDINGS CORPORATION : Ex-dividend day for final dividend
FA
More news
News in other languages on MEDIPAL HOLDINGS CORPORATION
07/29MEDIPAL HOLDINGS CORPORATION (TSE : 7459) a acquis une participation minoritaire inconnue ..
2018Medipal Holdings Corporation annonce ses résultats de bénéfices consolidés pour les neu..
2017MediPal Holdings Corporation annonce les résultats du bénéfice consolidé pour le semest..
2017Medipal Holdings Corporation annonce les résultats de son bénéfice consolidé pour le pr..
2017Medipal Holdings Corporation annonce les résultats des bénéfices consolidés et non cons..
More news
Chart MEDIPAL HOLDINGS CORPORATION
Duration : Period :
MediPal Holdings Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDIPAL HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 1 956,00 JPY
Average target price 2 156,67 JPY
Spread / Average Target 10,3%
EPS Revisions
Managers and Directors
Shuichi Watanabe Representative Director & Vice President
Takeshi Yanagida Senior Manager-Compliance
Yuji Sakon Managing Director & General Manager-Administration
Mitsuko Kagami Independent Outside Director
Kuniko Shoji Independent Director
Sector and Competitors